Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for treatment of corneal neovascularization
2009-017161-28Phase 4Terminated
- Sponsor
- Juha Holopainen
- Start
- Dec 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of bevacizumab in corneal neovascularization (CNV) (3 arms), sponsored by Juha Holopainen. Started Dec 2009; status: terminated.
02
Drugs
bevacizumab
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on 2009-017161-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017161-28.